SEARCH:   Advanced

This Article Full Text Full Text (PDF) Erratum (v91,p1100) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Greenberg, P. Articles by Bennett, J. Search for Related Content PubMed PubMed Citation Articles by Greenberg, P. Articles by Bennett, J. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  International scoring system for evaluating prognosis in myelodysplastic syndromes P Greenberg, C Cox, MM LeBeau, P Fenaux, P Morel, G Sanz, M Sanz, T Vallespi, T Hamblin, D Oscier, K Ohyashiki, K Toyama, C Aul, G Mufti and J Bennett Hematology Division, Stanford University Medical Center, CA 94305, USA. Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to improve on these systems, an International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems. A global analysis was performed on these patients, and critical prognostic variables were re-evaluated to generate a consensus prognostic system, particularly using a more refined bone marrow (BM) cytogenetic classification. Univariate analysis indicated that the major variables having an impact on disease outcome for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts, and number of cytopenias; for survival, in addition to the above, variables also included age and gender. Cytogenetic subgroups of outcome were as follows: "good" outcomes were normal, -Y alone, del(5q) alone, del(20q) alone; "poor" outcomes were complex (ie, > or = 3 abnormalities) or chromosome 7 anomalies; and "intermediate" outcomes were other abnormalities. Multivariate analysis combined these cytogenetic subgroups with percentage of BM blasts and number of cytopenias to generate a prognostic model. Weighting these variables by their statistical power separated patients into distinctive subgroups of risk for 25% of patients to undergo evolution to acute myeloid leukemia, with: low (31% of patients), 9.4 years; intermediate-1 (INT- 1; 39%), 3.3 years; INT-2 (22%), 1.1 years; and high (8%), 0.2 year. These features also separated patients into similar distinctive risk groups for median survival: low, 5.7 years; INT-1, 3.5 years; INT-2, 1.2 years; and high, 0.4 year. Stratification for age further improved analysis of survival. Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS. This classification system should prove useful for more precise design and analysis of therapeutic trials in this disease. Volume 89, Issue 6, pp. 2079-2088, 03/15/1997 Copyright © 1997 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Sridhar, D. T. Ross, R. Tibshirani, A. J. Butte, and P. L. Greenberg Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression Blood, November 26, 2009; 114(23): 4847 - 4858. [Abstract] [Full Text] [PDF] A. Tefferi and J. W. Vardiman Myelodysplastic Syndromes N. Engl. J. Med., November 5, 2009; 361(19): 1872 - 1885. [Full Text] [PDF] R. V. Tiu, L. P. Gondek, C. L. O'Keefe, J. Huh, M. A. Sekeres, P. Elson, M. A. McDevitt, X. F. Wang, M. J. Levis, J. E. Karp, et al. New Lesions Detected by Single Nucleotide Polymorphism Array-Based Chromosomal Analysis Have Important Clinical Impact in Acute Myeloid Leukemia J. Clin. Oncol., November 1, 2009; 27(31): 5219 - 5226. [Abstract] [Full Text] [PDF] O. Kosmider, V. Gelsi-Boyer, M. Cheok, S. Grabar, V. Della-Valle, F. Picard, F. Viguie, B. Quesnel, O. Beyne-Rauzy, E. Solary, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) Blood, October 8, 2009; 114(15): 3285 - 3291. [Abstract] [Full Text] [PDF] N. Galili, S. A. Qasim, and A. Raza Defective ribosome biogenesis in myelodysplastic syndromes Haematologica, October 1, 2009; 94(10): 1336 - 1338. [Full Text] [PDF] A. Czibere, I. Bruns, B. Junge, R. Singh, G. Kobbe, R. Haas, and U. Germing Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival Haematologica, October 1, 2009; 94(10): 1453 - 1455. [Abstract] [Full Text] [PDF] D. P. Steensma, J. D. Neiger, J. C. Porcher, J. J. Keats, P. L. Bergsagel, T. R. Dennis, R. A. Knudson, R. B. Jenkins, R. Santana-Davila, R. Kumar, et al. Rearrangements and Amplification of IER3 (IEX-1) Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes Cancer Res., October 1, 2009; 69(19): 7518 - 7523. [Abstract] [Full Text] [PDF] M. Y. Follo, C. Finelli, S. Mongiorgi, C. Clissa, C. Bosi, N. Testoni, F. Chiarini, G. Ramazzotti, M. Baccarani, A. M. Martelli, et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS PNAS, September 29, 2009; 106(39): 16811 - 16816. [Abstract] [Full Text] [PDF] B. Lowenberg, G. J. Ossenkoppele, W. van Putten, H. C. Schouten, C. Graux, A. Ferrant, P. Sonneveld, J. Maertens, M. Jongen-Lavrencic, M. von Lilienfeld-Toal, et al. High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia N. Engl. J. Med., September 24, 2009; 361(13): 1235 - 1248. [Abstract] [Full Text] [PDF] M. A. Sekeres and D. P. Steensma Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment Blood, September 24, 2009; 114(13): 2575 - 2580. [Abstract] [Full Text] [PDF] P. L. Greenberg, Z. Sun, K. B. Miller, J. M. Bennett, M. S. Tallman, G. Dewald, E. Paietta, R. van der Jagt, J. Houston, M. L. Thomas, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996) Blood, September 17, 2009; 114(12): 2393 - 2400. [Abstract] [Full Text] [PDF] S. Wei, X. Chen, K. Rocha, P. K. Epling-Burnette, J. Y. Djeu, Q. Liu, J. Byrd, L. Sokol, N. Lawrence, R. Pireddu, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide PNAS, August 4, 2009; 106(31): 12974 - 12979. [Abstract] [Full Text] [PDF] A. Orazi and M. B. Czader Myelodysplastic Syndromes Am J Clin Pathol, August 1, 2009; 132(2): 290 - 305. [Abstract] [Full Text] [PDF] A. A. van de Loosdrecht, C. Alhan, M. C. Bene, M. G. Della Porta, A. M. Drager, J. Feuillard, P. Font, U. Germing, D. Haase, C. H. Homburg, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes Haematologica, August 1, 2009; 94(8): 1124 - 1134. [Abstract] [Full Text] [PDF] K. Ogata, M. G. Della Porta, L. Malcovati, C. Picone, N. Yokose, A. Matsuda, T. Yamashita, H. Tamura, J. Tsukada, and K. Dan Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study Haematologica, August 1, 2009; 94(8): 1066 - 1074. [Abstract] [Full Text] [PDF] M. T. Voso, V. Santini, C. Finelli, P. Musto, E. Pogliani, E. Angelucci, G. Fioritoni, G. Alimena, L. Maurillo, A. Cortelezzi, et al. Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes Clin. Cancer Res., August 1, 2009; 15(15): 5002 - 5007. [Abstract] [Full Text] [PDF] K. I. Mills, A. Kohlmann, P. M. Williams, L. Wieczorek, W.-m. Liu, R. Li, W. Wei, D. T. Bowen, H. Loeffler, J. M. Hernandez, et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome Blood, July 30, 2009; 114(5): 1063 - 1072. [Abstract] [Full Text] [PDF] W. R. Sperr, F. Wimazal, M. Kundi, C. Baumgartner, T. Nosslinger, A. Makrai, R. Stauder, O. Krieger, M. Pfeilstocker, and P. Valent Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group Ann. Onc., July 15, 2009; (2009) mdp258v1. [Abstract] [Full Text] [PDF] T. Nosslinger, H. Tuchler, U. Germing, W. R. Sperr, O. Krieger, D. Haase, M. Lubbert, R. Stauder, A. Giagounidis, P. Valent, et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes Ann. Onc., July 15, 2009; (2009) mdp264v1. [Abstract] [Full Text] [PDF] U. Keilholz, A. Letsch, A. Busse, A. M. Asemissen, S. Bauer, I. W. Blau, W.-K. Hofmann, L. Uharek, E. Thiel, and C. Scheibenbogen A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS Blood, June 25, 2009; 113(26): 6541 - 6548. [Abstract] [Full Text] [PDF] A. Raza, N. Galili, S. Smith, J. Godwin, J. Lancet, M. Melchert, M. Jones, J. G. Keck, L. Meng, G. L. Brown, et al. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome Blood, June 25, 2009; 113(26): 6533 - 6540. [Abstract] [Full Text] [PDF] R. M. Stone How I treat patients with myelodysplastic syndromes Blood, June 18, 2009; 113(25): 6296 - 6303. [Full Text] [PDF] F. Delhommeau, S. Dupont, V. D. Valle, C. James, S. Trannoy, A. Masse, O. Kosmider, J.-P. Le Couedic, F. Robert, A. Alberdi, et al. Mutation in TET2 in Myeloid Cancers N. Engl. J. Med., May 28, 2009; 360(22): 2289 - 2301. [Abstract] [Full Text] [PDF] J. Uprichard and B. J Bain Investigating suspected anaemia BMJ, May 22, 2009; 338(may22_2): b1644 - b1644. [Full Text] S. Perreault and J. Burzynski Romiplostim: A novel thrombopoiesis-stimulating agent Am. J. Health Syst. Pharm., May 1, 2009; 66(9): 817 - 824. [Abstract] [Full Text] [PDF] E. Zipperer, D. Pelz, K. Nachtkamp, A. Kuendgen, C. Strupp, N. Gattermann, R. Haas, and U. Germing The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome Haematologica, May 1, 2009; 94(5): 729 - 732. [Abstract] [Full Text] [PDF] C. S. Tam, L. V. Abruzzo, K. I. Lin, J. Cortes, A. Lynn, M. J. Keating, D. A. Thomas, S. Pierce, H. Kantarjian, and S. Verstovsek The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course Blood, April 30, 2009; 113(18): 4171 - 4178. [Abstract] [Full Text] [PDF] L. Ades, S. Boehrer, T. Prebet, O. Beyne-Rauzy, L. Legros, C. Ravoet, F. Dreyfus, A. Stamatoullas, M. Pierre Chaury, J. Delaunay, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study Blood, April 23, 2009; 113(17): 3947 - 3952. [Abstract] [Full Text] [PDF] M. E.D. Chamuleau, T. M. Westers, L. van Dreunen, J. Groenland, A. Zevenbergen, C. M. Eeltink, G. J. Ossenkoppele, and A. A. van de Loosdrecht Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome Haematologica, April 1, 2009; 94(4): 496 - 506. [Abstract] [Full Text] [PDF] F. Cervantes, B. Dupriez, A. Pereira, F. Passamonti, J. T. Reilly, E. Morra, A. M. Vannucchi, R. A. Mesa, J.-L. Demory, G. Barosi, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood, March 26, 2009; 113(13): 2895 - 2901. [Abstract] [Full Text] [PDF] M. Heuser, D. B. Yap, M. Leung, T. R. de Algara, A. Tafech, S. McKinney, J. Dixon, R. Thresher, B. Colledge, M. Carlton, et al. Loss of Mll5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation Blood, February 12, 2009; 113(7): 1432 - 1443. [Abstract] [Full Text] [PDF] M. G. Della Porta, L. Malcovati, E. Boveri, E. Travaglino, D. Pietra, C. Pascutto, F. Passamonti, R. Invernizzi, A. Castello, U. Magrini, et al. Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes J. Clin. Oncol., February 10, 2009; 27(5): 754 - 762. [Abstract] [Full Text] [PDF] M. Y. Follo, C. Finelli, C. Clissa, S. Mongiorgi, C. Bosi, G. Martinelli, M. Baccarani, L. Manzoli, A. M. Martelli, and L. Cocco Phosphoinositide-Phospholipase C {beta}1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia J. Clin. Oncol., February 10, 2009; 27(5): 782 - 790. [Abstract] [Full Text] [PDF] T. S. Park, J. Song, J.-H. Lee, J. S. Kim, W. I. Yang, and J. R. Choi Concomitant Isochromosome 17q and Trisomy 14 in a Patient with Myelodysplastic Syndrome in Leukemic Transformation Ann. Clin. Lab. Sci., January 1, 2009; 39(2): 176 - 181. [Abstract] [Full Text] [PDF] G. Garcia-Manero Standard-of-care Approaches for Myelodysplastic Syndromes ASCO Educational Book, January 1, 2009; 2009(1): 408 - 412. [Abstract] [Full Text] [PDF] R. S. Komrokji and J. M. Bennett What Is "WHO"?: Myelodysplastic Syndrome Classification and Prognosis ASCO Educational Book, January 1, 2009; 2009(1): 413 - 419. [Abstract] [Full Text] [PDF] H. J. Deeg Allogeneic Hematopoietic Cell Transplantation in Older Patients with Myelodysplastic Syndrome ASCO Educational Book, January 1, 2009; 2009(1): 420 - 424. [Abstract] [Full Text] [PDF] M. A. Sekeres, J. P. Maciejewski, A. A.N. Giagounidis, K. Wride, R. Knight, A. Raza, and A. F. List Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes J. Clin. Oncol., December 20, 2008; 26(36): 5943 - 5949. [Abstract] [Full Text] [PDF] M. A. Sekeres, W. M. Schoonen, H. Kantarjian, A. List, J. Fryzek, R. Paquette, and J. P. Maciejewski Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys J Natl Cancer Inst, November 5, 2008; 100(21): 1542 - 1551. [Abstract] [Full Text] [PDF] G. J. Mufti, J. M. Bennett, J. Goasguen, B. J. Bain, I. Baumann, R. Brunning, M. Cazzola, P. Fenaux, U. Germing, E. Hellstrom-Lindberg, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts Haematologica, November 1, 2008; 93(11): 1712 - 1717. [Abstract] [Full Text] [PDF] L. Zhou, A. N. Nguyen, D. Sohal, J. Ying Ma, P. Pahanish, K. Gundabolu, J. Hayman, A. Chubak, Y. Mo, T. D. Bhagat, et al. Inhibition of the TGF-{beta} receptor I kinase promotes hematopoiesis in MDS Blood, October 15, 2008; 112(8): 3434 - 3443. [Abstract] [Full Text] [PDF] D. T. Starczynowski, S. Vercauteren, A. Telenius, S. Sung, K. Tohyama, A. Brooks-Wilson, J. J. Spinelli, C. J. Eaves, A. C. Eaves, D. E. Horsman, et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival Blood, October 15, 2008; 112(8): 3412 - 3424. [Abstract] [Full Text] [PDF] B. L. Scott, D. A. Wells, M. R. Loken, D. Myerson, W. M. Leisenring, and H. J. Deeg Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome Blood, October 1, 2008; 112(7): 2681 - 2686. [Abstract] [Full Text] [PDF] A. A. Di Tucci, G. Matta, S. Deplano, A. Gabbas, C. Depau, D. Derudas, G. Caocci, A. Agus, and E. Angelucci Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias Haematologica, September 1, 2008; 93(9): 1385 - 1388. [Abstract] [Full Text] [PDF] J. P. Maciejewski and G. J. Mufti Whole genome scanning as a cytogenetic tool in hematologic malignancies Blood, August 15, 2008; 112(4): 965 - 974. [Abstract] [Full Text] [PDF] E. P. Alessandrino, M. G. Della Porta, A. Bacigalupo, M. T. Van Lint, M. Falda, F. Onida, M. Bernardi, A. P. Iori, A. Rambaldi, R. Cerretti, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Blood, August 1, 2008; 112(3): 895 - 902. [Abstract] [Full Text] [PDF] M. Jadersten, L. Malcovati, I. Dybedal, M. Giovanni Della Porta, R. Invernizzi, S. M. Montgomery, C. Pascutto, A. Porwit, M. Cazzola, and E. Hellstrom-Lindberg Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome J. Clin. Oncol., July 20, 2008; 26(21): 3607 - 3613. [Abstract] [Full Text] [PDF] M. Mallo, L. Arenillas, B. Espinet, M. Salido, J. M{a} Hernandez, E. Lumbreras, M. del Rey, E. Arranz, S. Ramiro, P. Font, et al. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q- Haematologica, July 1, 2008; 93(7): 1001 - 1008. [Abstract] [Full Text] [PDF] E. M. Sloand, C. O. Wu, P. Greenberg, N. Young, and J. Barrett Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy J. Clin. Oncol., May 20, 2008; 26(15): 2505 - 2511. [Abstract] [Full Text] [PDF] S. D. Nimer Myelodysplastic syndromes Blood, May 15, 2008; 111(10): 4841 - 4851. [Abstract] [Full Text] [PDF] T. Hamada, H. Matsuura, T. Oono, S. Morizane, O. Yamasaki, K. Asagoe, T. Yamamoto, K. Tsuji, and K. Iwatsuki Karyotypic Analysis of Bone Marrow Cells in Pyodermic Lesions Associated With Myelodysplastic Syndrome Arch Dermatol, May 1, 2008; 144(5): 643 - 648. [Abstract] [Full Text] [PDF] F. Wimazal, W. R. Sperr, M. Kundi, A. Vales, C. Fonatsch, R. Thalhammer-Scherrer, I. Schwarzinger, and P. Valent Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes Ann. Onc., May 1, 2008; 19(5): 970 - 976. [Abstract] [Full Text] [PDF] L. Malcovati, M. Cazzola, and U. Germing In Reply J. Clin. Oncol., March 1, 2008; 26(7): 1181 - 1182. [Full Text] [PDF] J.-J. Kiladjian, G. Visentin, E. Viey, S. Chevret, V. Eclache, J. Stirnemann, J. H. Bourhis, S. Chouaib, P. Fenaux, and A. Caignard Activation of cytotoxic T-cell receptor {gamma}{delta} T lymphocytes in response to specific stimulation in myelodysplastic syndromes Haematologica, March 1, 2008; 93(3): 381 - 389. [Abstract] [Full Text] [PDF] D. Valcarcel, R. Martino, D. Caballero, J. Martin, C. Ferra, J. B. Nieto, A. Sampol, M. T. Bernal, J. L. Pinana, L. Vazquez, et al. Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival J. Clin. Oncol., February 1, 2008; 26(4): 577 - 584. [Abstract] [Full Text] [PDF] L. P. Gondek, R. Tiu, C. L. O'Keefe, M. A. Sekeres, K. S. Theil, and J. P. Maciejewski Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML Blood, February 1, 2008; 111(3): 1534 - 1542. [Abstract] [Full Text] [PDF] A. A. van de Loosdrecht, T. M. Westers, A. H. Westra, A. M. Drager, V. H. J. van der Velden, and G. J. Ossenkoppele Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry Blood, February 1, 2008; 111(3): 1067 - 1077. [Abstract] [Full Text] [PDF] R. Kurzrock, H. M. Kantarjian, M. A. Blascovich, C. Bucher, S. Verstovsek, J. J. Wright, S. R. Pilat, J. E. Cortes, E. H. Estey, F. J. Giles, et al. Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome Clin. Cancer Res., January 15, 2008; 14(2): 509 - 514. [Abstract] [Full Text] [PDF] S. Park, S. Grabar, C. Kelaidi, O. Beyne-Rauzy, F. Picard, V. Bardet, V. Coiteux, G. Leroux, P. Lepelley, M.-T. Daniel, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience Blood, January 15, 2008; 111(2): 574 - 582. [Abstract] [Full Text] [PDF] M. Cazzola, M. G. Della Porta, and L. Malcovati Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes Hematology, January 1, 2008; 2008(1): 166 - 175. [Abstract] [Full Text] [PDF] A. Raza, J. A. Reeves, E. J. Feldman, G. W. Dewald, J. M. Bennett, H. J. Deeg, L. Dreisbach, C. A. Schiffer, R. M. Stone, P. L. Greenberg, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q Blood, January 1, 2008; 111(1): 86 - 93. [Abstract] [Full Text] [PDF] D. Haase, U. Germing, J. Schanz, M. Pfeilstocker, T. Nosslinger, B. Hildebrandt, A. Kundgen, M. Lubbert, R. Kunzmann, A. A. N. Giagounidis, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood, December 15, 2007; 110(13): 4385 - 4395. [Abstract] [Full Text] [PDF] M. Grovdal, R. Khan, A. Aggerholm, P. Antunovic, J. Astermark, P. Bernell, L.-M. Engstrom, L. Kjeldsen, O. Linder, L. Nilsson, et al. Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome Clin. Cancer Res., December 1, 2007; 13(23): 7107 - 7112. [Abstract] [Full Text] [PDF] A. Mohamedali, J. Gaken, N. A. Twine, W. Ingram, N. Westwood, N. C. Lea, J. Hayden, N. Donaldson, C. Aul, N. Gattermann, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes Blood, November 1, 2007; 110(9): 3365 - 3373. [Abstract] [Full Text] [PDF] S. D. Ross, I. E. Allen, C. A. Probst, B. Sercus, S. M. Crean, and G. Ranganathan Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis Oncologist, October 1, 2007; 12(10): 1264 - 1273. [Abstract] [Full Text] [PDF] M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation J. Clin. Oncol., September 20, 2007; 25(27): 4246 - 4254. [Abstract] [Full Text] [PDF] C. Chang, B. E. Storer, B. L. Scott, E. M. Bryant, H. M. Shulman, M. E. Flowers, B. M. Sandmaier, R. P. Witherspoon, R. A. Nash, J. E. Sanders, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders Blood, August 15, 2007; 110(4): 1379 - 1387. [Abstract] [Full Text] [PDF] L. Malcovati, U. Germing, A. Kuendgen, M. G. Della Porta, C. Pascutto, R. Invernizzi, A. Giagounidis, B. Hildebrandt, P. Bernasconi, S. Knipp, et al. Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes J. Clin. Oncol., August 10, 2007; 25(23): 3503 - 3510. [Abstract] [Full Text] [PDF] T. Siitonen, T. Timonen, E. Juvonen, V. Terava, A. Kutila, T. Honkanen, M. Mikkola, H. Hallman, M. Kauppila, P. Nylanden, et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes Haematologica, August 1, 2007; 92(8): 1119 - 1122. [Abstract] [Full Text] [PDF] U. Germing, C. Strupp, S. Knipp, A. Kuendgen, A. Giagounidis, B. Hildebrandt, C. Aul, R. Haas, N. Gattermann, and J. M. Bennett Chronic myelomonocytic leukemia in the light of the WHO proposals Haematologica, July 1, 2007; 92(7): 974 - 977. [Abstract] [Full Text] [PDF] D. P. Steensma The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia Haematologica, June 1, 2007; 92(6): 723 - 727. [Full Text] [PDF] U. Bacher, T. Haferlach, W. Kern, C. Haferlach, and S. Schnittger A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia Haematologica, June 1, 2007; 92(6): 744 - 752. [Abstract] [Full Text] [PDF] P. Fenaux, A. Raza, G. J. Mufti, C. Aul, U. Germing, H. Kantarjian, L. Cripe, R. Kerstens, P. De Porre, and R. Kurzrock A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome Blood, May 15, 2007; 109(10): 4158 - 4163. [Abstract] [Full Text] [PDF] E. Estey Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients J. Clin. Oncol., May 10, 2007; 25(14): 1908 - 1915. [Abstract] [Full Text] [PDF] M. Y. Follo, S. Mongiorgi, C. Bosi, A. Cappellini, C. Finelli, F. Chiarini, V. Papa, M. Libra, G. Martinelli, L. Cocco, et al. The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation Cancer Res., May 1, 2007; 67(9): 4287 - 4294. [Abstract] [Full Text] [PDF] Y. A. Boumber, Y. Kondo, X. Chen, L. Shen, V. Gharibyan, K. Konishi, E. Estey, H. Kantarjian, G. Garcia-Manero, and J.-P. J. Issa RIL, a LIM Gene on 5q31, Is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis Cancer Res., March 1, 2007; 67(5): 1997 - 2005. [Abstract] [Full Text] [PDF] M. Aivado, D. Spentzos, U. Germing, G. Alterovitz, X.-Y. Meng, F. Grall, A. A. N. Giagounidis, G. Klement, U. Steidl, H. H. Otu, et al. From the cover: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease PNAS, January 23, 2007; 104(4): 1307 - 1312. [Abstract] [Full Text] [PDF] A. Ganser, M. A. Morgan, and E. M. Weissinger Going from genes to proteins in myelodysplastic syndromes PNAS, January 23, 2007; 104(4): 1109 - 1110. [Full Text] [PDF] W. Barcellini, A. Zaninoni, F. G. Imperiali, C. Boschetti, M. Colombi, A. Iurlo, and A. Zanella Anti-erythroblast autoimmunity in early myelodysplastic syndromes Haematologica, January 1, 2007; 92(1): 19 - 26. [Abstract] [Full Text] [PDF] J. Pedersen-Bjergaard, M. T. Andersen, and M. K. Andersen Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia Hematology, January 1, 2007; 2007(1): 392 - 397. [Abstract] [Full Text] [PDF] M. Melchert and A. F. List Management of RBC-Transfusion Dependence Hematology, January 1, 2007; 2007(1): 398 - 404. [Abstract] [Full Text] [PDF] G. Garcia-Manero Modifying the Epigenome as a Therapeutic Strategy in Myelodysplasia Hematology, January 1, 2007; 2007(1): 405 - 411. [Abstract] [Full Text] [PDF] K. Shannon and L. R. Silverman Myelodysplastic syndrome and overlap syndromes ASH Self-Assessment Program, January 1, 2007; 2007(1): 228 - 242. [Full Text] [PDF] T. A. Navas, M. Mohindru, M. Estes, J. Y. Ma, L. Sokol, P. Pahanish, S. Parmar, E. Haghnazari, L. Zhou, R. Collins, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors Blood, December 15, 2006; 108(13): 4170 - 4177. [Abstract] [Full Text] [PDF] A. Kuendgen, C. Strupp, M. Aivado, B. Hildebrandt, R. Haas, N. Gattermann, and U. Germing Myelodysplastic Syndromes in Patients Younger Than Age 50 J. Clin. Oncol., December 1, 2006; 24(34): 5358 - 5365. [Abstract] [Full Text] [PDF] A. List, G. Dewald, J. Bennett, A. Giagounidis, A. Raza, E. Feldman, B. Powell, P. Greenberg, D. Thomas, R. Stone, et al. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion N. Engl. J. Med., October 5, 2006; 355(14): 1456 - 1465. [Abstract] [Full Text] [PDF] A. Agool, B. W. Schot, P. L. Jager, and E. Vellenga 18F-FLT PET in Hematologic Disorders: A Novel Technique to Analyze the Bone Marrow Compartment J. Nucl. Med., October 1, 2006; 47(10): 1592 - 1598. [Abstract] [Full Text] [PDF] H. Szpurka, R. Tiu, G. Murugesan, S. Aboudola, E. D. Hsi, K. S. Theil, M. A. Sekeres, and J. P. Maciejewski Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation Blood, October 1, 2006; 108(7): 2173 - 2181. [Abstract] [Full Text] [PDF] R. Martino, S. Iacobelli, R. Brand, T. Jansen, A. van Biezen, J. Finke, A. Bacigalupo, D. Beelen, J. Reiffers, A. Devergie, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes Blood, August 1, 2006; 108(3): 836 - 846. [Abstract] [Full Text] [PDF] K. Ogata, Y. Kishikawa, C. Satoh, H. Tamura, K. Dan, and A. Hayashi Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes Blood, August 1, 2006; 108(3): 1037 - 1044. [Abstract] [Full Text] [PDF] B. D. Cheson, P. L. Greenberg, J. M. Bennett, B. Lowenberg, P. W. Wijermans, S. D. Nimer, A. Pinto, M. Beran, T. M. de Witte, R. M. Stone, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood, July 15, 2006; 108(2): 419 - 425. [Abstract] [Full Text] [PDF] A. Pellagatti, M. Cazzola, A. A. N. Giagounidis, L. Malcovati, M. G. D. Porta, S. Killick, L. J. Campbell, L. Wang, C. F. Langford, C. Fidler, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype Blood, July 1, 2006; 108(1): 337 - 345. [Abstract] [Full Text] [PDF] S. D. Gore, S. Baylin, E. Sugar, H. Carraway, C. B. Miller, M. Carducci, M. Grever, O. Galm, T. Dauses, J. E. Karp, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res., June 15, 2006; 66(12): 6361 - 6369. [Abstract] [Full Text] [PDF] T. Buchner, W. E. Berdel, C. Schoch, T. Haferlach, H. L. Serve, J. Kienast, S. Schnittger, W. Kern, J. Tchinda, A. Reichle, et al. Double Induction Containing Either Two Courses or One Course of High-Dose Cytarabine Plus Mitoxantrone and Postremission Therapy by Either Autologous Stem-Cell Transplantation or by Prolonged Maintenance for Acute Myeloid Leukemia J. Clin. Oncol., June 1, 2006; 24(16): 2480 - 2489. [Abstract] [Full Text] [PDF] R. M. Stone Is Intravenous Arsenic Trioxide a Useful Therapy in Myelodysplastic Syndromes? J. Clin. Oncol., June 1, 2006; 24(16): 2414 - 2416. [Full Text] [PDF] J. K. Davies, D. C. Taussig, H. Oakervee, A. J. Davies, S. G. Agrawal, J. G. Gribben, T. A. Lister, and J. D. Cavenagh Long-Term Follow-Up After Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome: Late CNS Relapses Despite Graft-Versus-Host Disease J. Clin. Oncol., May 10, 2006; 24(14): e23 - e25. [Full Text] [PDF]

	Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020